Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $215M in Series B funding.
The round was led by Wellington Management and Venrock, with participation from Fidelity Management and Research Company, Janus Henderson Investors, T. Rowe Price Associates, T. Rowe Price Investment Management, Viking Global Investors, Deep Track Capital, RA Capital Management, ARCH Venture Partners, Alpha Wave Ventures, GV, SoftBank Vision Fund 2, Newpath Partners, SymBiosis, and other undisclosed investors.
The company intends to use the funds to further advance its portfolio of clinical-stage, Nutrient-Stimulated Hormone (NuSH) analog peptides.
Founded in 2022 by Population Health Partners and ARCH Venture Partners and led by CEO Whit Bernard, Metsera is a clinical-stage biopharmaceutical company accelerating medicines for obesity and metabolic diseases. It is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
The company has raised over $500M to date.
FinSMEs
14/11/2024